Attention!

What is the drug LAPATINIB-CHEMRAR

The drug LAPATINIB-CHEMRAR contains the active substance lapatinib, which belongs to the group of drugs called "antitumor agents; protein kinase inhibitors; tyrosine kinase inhibitors of the human epidermal growth factor receptor type 2 (HER-2)".

Dosage form and packaging

Film-coated tablets.

Oval biconvex tablets covered with a film-coated light yellow color. On a cross-section, the core is yellow to yellow-green in color.

70 or 140 tablets in a plastic bottle, sealed with a polypropylene cap with a desiccant, child protection and first opening control.

1 bottle with a leaflet insert is placed in a pack of cardboard.

Indications for use

LAPATINIB-CHEMRAR is indicated for use in adults over the age of 18 years for the treatment of breast cancer that has spread beyond the original tumor or to other organs (locally advanced or metastatic breast cancer) and in which the amount of a certain protein increases in cancer cells (overexpression of NER2).

The drug LAPATINIB-CHEMRAR is taken together with one of the following antitumor drugs:

- in combination with capecitabine (if previously treated with metastatic breast cancer using trastuzumab, anthracyclines and taxanes);

- with trastuzumab (if certain hormone receptors are missing and metastatic breast cancer has previously been treated with trastuzumab along with other anticancer drugs);

- with aromatase inhibitors (if the period is postmenopausal and a hormone-sensitive variant of breast cancer is detected).

Efficacy and safety studies

In accordance with current legislation, the drug has proven its effectiveness, safety and quality during state registration. For registration purposes, a bioequivalence study was conducted with the original (reference) medicinal product.